Brief: Fate Therapeutics Says Bob Valamehr To Become President, CEO As Of Jan 2025
29/11/2024 18:16
Nov 29 (Reuters) - Fate Therapeutics Inc FATE.O :
* FATE THERAPEUTICS ANNOUNCES LEADERSHIP TRANSITION
* FATE THERAPEUTICS INC - SCOTT WOLCHKO TO RETIRE AS
PRESIDENT AND
CEO DEC 31, 2024
* FATE THERAPEUTICS INC - BOB VALAMEHR TO BECOME PRESIDENT
AND CEO
JAN 1, 2025
* FATE THERAPEUTICS INC - SCOTT WOLCHKO TO CONTINUE AS
STRATEGIC
ADVISOR
Source text: ID:nGNXYWfDk
Further company coverage: FATE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Fate Therapeutics
See all newsBrief: Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial Of FT819 For The Treatment Of Lupus Nephritis
Fate Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Fate Therapeutics Q2 loss narrows as expenses fall, revenue rises
Fate Therapeutics Inc expected to post a loss of 27 cents a share - Earnings Preview
Fate Therapeutics Inc expected to post a loss of 27 cents a share - Earnings Preview